The management of coeliac disease is an increasing part of a gastroenterologist’s workload. Recent prevalence studies suggest ~1% of the general UK population have positive coeliac serology, which combined with increasing population and primary care awareness is leading to more and more referrals. The majority of contemporary referrals are now initially diagnosed by highly sensitive and specific serological tests followed by readily performed endoscopic biopsy (fig 1). Consequently, we now identify many more patients with no or only mild clinical symptoms, making the classical scenario of diarrhoea/steatorrhoea and weight loss a comparative rarity. Much of the early data on clinical aspects of classical coeliac disease (that is, published pre ~1990) may not be applicable to contemporary coeliac disease. These changes in clinical practice have been paralleled by a dramatic increase in our knowledge of disease pathogenesis, making coeliac disease the best understood human “autoimmune” disorder. In this review article, we present selected major recent advances in both clinical and basic science aspects of coeliac disease, focusing on the many high quality studies published within the last five years.

**General population based prevalence studies of undetected coeliac disease**

Several serological screening studies from Europe, South America, Australasia, and the USA have shown that approximately 0.5–1% of these populations may have undetected coeliac disease. The most consistent estimate reported from the largest population based studies is approximately 1%. The prevalence is even higher in first and second degree relatives of people with coeliac disease.1

In the five studies shown in table 1, general population based samples of children were recruited for coeliac disease screening. The two earlier Italian studies (using antigliadin antibody testing followed by antiendomysial antibody and small bowel biopsy) suggested a prevalence of 1 in 93 of undetected coeliac disease.2 3 These findings have been replicated in two further large studies, one from the UK and one from Finland. The recent Bristol study used blood stored anonymously for the Avon Longitudinal Study of Parents and Children (a population based birth cohort study established in 1990).4 This study tested 5470 children for antitissue transglutaminase antibody and then those who were positive with a further antiendomysial antibody test. Maki et al tested 3654 Finnish students for both serological tests and offered small intestinal biopsy to those who were positive.5 Both of these studies found a prevalence of approximately 1 in 100.

The study of Saharawi children by Catassi et al showed the highest coeliac disease prevalence (5%).6 This cohort, comprising refugees living in an Algerian province, was tested for antiendomysial antibody and a sample of positive individuals had small intestinal mucosa biopsy. Reasons for this high prevalence, which is markedly different to all the other general population estimates, are unclear. The authors speculated that coeliac disease might confer some “protection” against intestinal infections or parasites.

Selected adult general population based screening studies for coeliac disease are shown in table 2. Three of these studies used populations recruited for the World Health Organisation MONICA project (monitoring of trends and determinants in cardiovascular disease) and were similar in design, with samples randomly selected from population registers stratified by age and sex.7 8 All three of these studies (and the Argentinean study) used a combination of antigliadin antibody and antiendomysial antibody testing to identify people with previously undetected coeliac disease, but not all reported small intestinal biopsy. Other studies used antiendomysial antibody as the main test for identifying people with undetected coeliac disease.

It is notable that the prevalence of undetected coeliac disease in both children and adults is very similar (approximately 1%) in the two recent large UK based studies.4 10 It therefore seems probable that the coeliac trait starts in early childhood in all cases, even in those who are subsequently diagnosed as adults. The search for the initial trigger resulting in the breakdown of oral tolerance to dietary wheat, rye, and barley therefore needs to focus on in utero events and
early infancy. Why some adults suddenly develop symptoms in later life is unexplained and might reflect a later event in the control of immunological tolerance.

**Prevalence studies of clinically diagnosed coeliac disease**

Estimates of the prevalence of clinically diagnosed coeliac disease range from approximately 0.05% to 0.27%. From data in Derby, UK, the estimated prevalence of clinically diagnosed coeliac disease at the end of 1999 was 0.14%. These figures suggest that the current ratio (prevalence based) of clinically diagnosed to undetected cases—that is, “the size of the iceberg”—in the UK is approximately 1 in 8.

**Incidence of coeliac disease in children and adults**

Studies of childhood coeliac disease in the UK showed a general decline in incidence during the 1970s. Other countries, apart from Sweden, have also reported some evidence of a decline. More recently, some studies have suggested that the incidence of childhood coeliac disease may have been rising during the late 1980s and 1990s. There are differences across studies in case identification method: the use of hospital admission data, self- or parent reported diagnosis, and national coeliac society membership—all of which are liable to variation by ascertainment and therefore might explain some of the differences.

Data from Sweden reported by Ivarsson et al related the rise in childhood coeliac disease to infant feeding practices. The “Swedish epidemic” suggested that coeliac disease might be prevented in part by introduction of gluten while still breast feeding, and gluten introduction between 4 and 6 months of life, rather than before or after. It is plausible that these factors may help induce oral tolerance to dietary antigens in susceptible individuals. However, a recent population based study from the Netherlands reported no such change in infant feeding practices during the period studied, yet there was an increase in incidence.

The rate of diagnosis of adult coeliac disease has risen dramatically in most areas of the world where there are data available to monitor such trends. The estimated annual rate of diagnoses from various areas is shown in fig 2. An interest in coeliac disease research in some centres probably combined with an active “case finding” strategy may explain the variation apparent in these figures. In combination with the diagnosed disease prevalence estimates they do indicate the substantial gap between the number of people with clinically diagnosed and undetected disease.

**CLINICAL MANIFESTATIONS OF COELIAC DISEASE**

Although coeliac disease can be diagnosed at any age, it presents most commonly in either early childhood (between 9 and 24 months) or in the third or fourth decade of life. In contrast to the 1:1 sex ratio in children, twice as many females are diagnosed in adulthood. Although the “classical” gastrointestinal malabsorption syndrome characterised by diarrhoea, steatorrhea, weight loss, fatigue, and anaemia may occur in severe cases, most patients have a milder constellation of symptoms such as abdominal discomfort, bloating, indigestion, or non-gastrointestinal symptoms (or no symptoms at all). Since coeliac disease was first described, the clinical manifestation seen in the UK appears to be changing, with increasing numbers being diagnosed as a result of the investigation of anaemia and/or non-classical symptoms.

---

**Table 1**

<table>
<thead>
<tr>
<th>Area</th>
<th>Year, citation</th>
<th>Age (y)*</th>
<th>Proportion male (%)</th>
<th>Cases</th>
<th>No screened</th>
<th>Prevalence (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Italy</td>
<td>1994*</td>
<td>13</td>
<td>50</td>
<td>11</td>
<td>3351</td>
<td>0.33% (0.16–0.59)</td>
</tr>
<tr>
<td>Italy</td>
<td>1999*</td>
<td>6–14</td>
<td>53</td>
<td>17</td>
<td>1607</td>
<td>1.06% (0.62–1.69)</td>
</tr>
<tr>
<td>Sahara</td>
<td>1999*</td>
<td>7.4</td>
<td>53</td>
<td>56</td>
<td>989</td>
<td>5.66% (4.21–7.29)</td>
</tr>
<tr>
<td>Finland</td>
<td>2003*</td>
<td>7–16</td>
<td>–</td>
<td>37</td>
<td>3654</td>
<td>1.01% (0.71–1.39)</td>
</tr>
<tr>
<td>UK (Bristol)</td>
<td>2004*</td>
<td>7.5</td>
<td>–</td>
<td>54</td>
<td>5470</td>
<td>0.99% (0.74–1.29)</td>
</tr>
</tbody>
</table>

*Mean (range).
†Prevalence (%) calculated from available data, with 95% confidence interval (CI) calculated using binomial distribution.
Hin et al recently carried out a case finding study in primary care in the UK. In this study, individuals with fatigue and/or with a past or present diagnosis of microcytic anaemia had the highest prevalence of previously undetected coeliac disease.

One explanation for any changes in presentation could be that the natural history of the disease is changing, perhaps in response to changing environmental stimuli such as infant feeding practices in children or cigarette smoking in adults. A more likely explanation is that the ability to make the diagnosis has improved (both better tests and greater test accessibility) throughout the last 20 years with the development of accurate serological markers of the disease and increasing use of endoscopic biopsy techniques. Therefore, a much broader spectrum of individuals are being investigated for coeliac disease and consequently being diagnosed (fig 1).

**IMPACT OF UNDETECTED COELIAC DISEASE**

The implications of recognising undetected coeliac disease at a general population level are unclear because the few reported data on the morbidity and physiological characteristics associated with previously undetected disease are from small selected case series. Few studies so far have been able to analyse a wide variety of sociodemographic and physiological factors with respect to undiagnosed coeliac disease due to low sample size. Most adult screening studies in the general population have identified only small numbers of previously undiagnosed cases and have therefore been unable to examine any associations in comparison with the general population. Of the studies that have looked at the differences between clinically diagnosed disease and “screening” or previously undetected disease, most have focused on bone mineral density and anthropometric measurements. The findings suggest that people with undetected coeliac disease have a slight tendency towards low bone density and measurements in keeping with mildly subnormal nutritional status.

Analysis of a population based cohort from Cambridge, UK, showed that there were some negative health effects of undetected coeliac disease, for example mild anaemia and osteoporosis. However, the study findings implied a reduced risk of cardiovascular disease from the observations of lower body mass index, lower blood pressure, and lower serum cholesterol in people with undetected coeliac disease. This effect, of potentially large impact, requires confirmation and further epidemiological assessment.

**IMPACT OF CLINICALLY DIAGNOSED COELIAC DISEASE**

**Osteoporosis and fracture**

As a consequence of osteoporosis there may be an increased risk of fracture in people with coeliac disease. Due to this perceived increase in fracture risk, some groups (including the British Society of Gastroenterology) have recommended screening and surveillance of people with coeliac disease for increased bone mineral density in order to implement treatment with bisphosphonates or hormone replacement therapy.

**Table 2 Coeliac disease prevalence in general population based studies: adults**

<table>
<thead>
<tr>
<th>Area</th>
<th>Year, citation</th>
<th>Age (y)*</th>
<th>Proportion male (%)</th>
<th>Cases</th>
<th>No screened</th>
<th>Prevalence (95% CI)†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ireland</td>
<td>1997†</td>
<td>15–65</td>
<td>–</td>
<td>15</td>
<td>1823</td>
<td>0.82 (0.46–1.33)</td>
</tr>
<tr>
<td>Italy</td>
<td>1997‡</td>
<td>44 (20–89)</td>
<td>47</td>
<td>4</td>
<td>2237</td>
<td>0.18 (0.05–0.46)</td>
</tr>
<tr>
<td>Sweden</td>
<td>1999†</td>
<td>50 (25–74)</td>
<td>50</td>
<td>10</td>
<td>1894</td>
<td>0.53 (0.25–0.97)</td>
</tr>
<tr>
<td>Spain</td>
<td>2000‡</td>
<td>45 (2–89)</td>
<td>45</td>
<td>3</td>
<td>1170</td>
<td>0.26 (0.05–0.75)</td>
</tr>
<tr>
<td>France</td>
<td>2000</td>
<td>35–64</td>
<td>–</td>
<td>3</td>
<td>1163</td>
<td>0.26 (0.05–0.75)</td>
</tr>
<tr>
<td>Italy</td>
<td>2001‡</td>
<td>12–65</td>
<td>48</td>
<td>17</td>
<td>3483</td>
<td>0.49 (0.28–0.78)</td>
</tr>
<tr>
<td>Argentina</td>
<td>2001‡</td>
<td>16–79</td>
<td>50</td>
<td>12</td>
<td>2000</td>
<td>0.60 (0.31–1.05)</td>
</tr>
<tr>
<td>Australia</td>
<td>2001‡</td>
<td>20–79</td>
<td>50</td>
<td>7</td>
<td>3011</td>
<td>0.23 (0.09–0.48)</td>
</tr>
<tr>
<td>England</td>
<td>2003</td>
<td>59 (45–76)</td>
<td>41</td>
<td>87</td>
<td>7527</td>
<td>1.2 (0.9–1.4)</td>
</tr>
</tbody>
</table>

*Mean (range).
†Prevalence (%) calculated from available data, with 95% confidence interval (CI) calculated using the binomial distribution.

**Figure 2** Estimated annual rate of diagnosis (by quinquennia) of coeliac disease from various geographical areas.
Some estimates of the excess fracture risk experienced by people with coeliac disease in comparison with the general population are available. Vasquez et al compared the fracture experience of 165 patients with that of controls with functional gastrointestinal disorders and found a threefold increase in overall fracture risk. A subsequent study from the same group found that the increase in fracture experience was confined to patients with coeliac disease presenting with “classical malabsorption” (odds ratio 5) compared with matched controls. Fickling et al reported a “relative risk” of fracture of 7 based on a survey of 75 patients and matched controls selected from patients who had attended for bone densitometry.

More recent data from larger series however point to a much smaller increased fracture risk in coeliac disease. Both Westergaard and Mosekilde, in a database study of 1021 hospital diagnosed subjects with coeliac disease, and Thomason et al, using a mailed questionnaire survey of 244 cases, found no increase in the overall fracture risk compared with the general population but with wide confidence limits. West et al, who used a population based cohort study involving 4732 people with coeliac disease, showed that overall there was a small increased risk of fracture in those with coeliac disease. The risks of “osteoporotic” fracture such as hip (rate ratio 1.9), ulna/radius (rate ratio 1.8), and vertebral (rate ratio 1.5; J West unpublished data) were higher than the overall risk but were, at most, moderate. Translating these data into follow up of 1000 people with coeliac disease for one year compared with a similar group from the general population means only one extra hip fracture during the year.

Some groups have suggested that all newly diagnosed adults with coeliac disease should be screened for osteoporosis, using DEXA scanning, either at diagnosis or following one year of treatment with a gluten free diet. Overall the current research data would suggest that more studies are needed on the safety, efficacy, and cost effectiveness of such screening programmes before they are universally recommended.

Malignancy and mortality

Early studies of the risk of malignancy and mortality in patients with coeliac disease suggested a twofold increase in mortality rate, and greatly increased risks of lymphoproliferative malignancies. Most studies have been small or not population based, and their findings probably do not reflect the risks in contemporary coeliac disease. More recent data from Sweden based on cases from hospital inpatient registers have suggested more modest increases in the risks but still found that people with coeliac disease were at excess risk of certain malignancies and death. Although large and population based, these studies were dependent on hospital admission of the index case for ascertainment, and thus may be biased towards overestimation of the risks. A further study from Derby, UK, showed that for a large cohort of people with coeliac disease followed up for nearly 25 years there was no overall increase in malignancy risk. This study, the absolute risk of non-Hodgkin’s lymphoma was 1 in 1421 person years and for small bowel lymphoma 1 in 5684 person years, indicating the rarity of the occurrence of such malignancies. The majority of other studies have found overall increased risks for malignancy or mortality of twofold or greater but these studies have been in cohorts of people with coeliac disease diagnosed and followed up some time ago, or from specialist referral centres.

Interestingly, four studies have suggested a decrease in the risk of breast cancer in people with coeliac disease, the reasons for which are not clear.

Recent findings from the UK General Practice Research Database are more consistent with the modest risks observed in Sweden. In this study, people with diagnosed coeliac disease had modest increases in the relative and absolute risk of malignancy and mortality. Most of the excess risk occurred in the first year after diagnosis and suggest that in treated coeliac disease the excess risk of cancer and shortened life expectancy are low.

Fertility

Previous research has suggested that coeliac disease, along with other chronic inflammatory diseases, may be associated with reduced fertility and increased risk of adverse pregnancy related events. Some have accepted that infertility is indeed a complication of coeliac disease and if true this is of importance to both women with coeliac disease and to those who manage their care. Reported associations between coeliac disease and a higher incidence of termination, miscarriage, and having babies with low birth weight or intrauterine growth retardation, have also raised concern.

Recent work compared the fertility experience of 1521 UK women with coeliac disease to women in the general population using the General Practice Research Database. Women with coeliac disease had similar fertility rates to the general female population but tended to have babies at a later age. As the patterns of later fertility for the untreated group versus the treated group were similar, when restricted to incident patients, it seems unlikely that the cause of this later fertility is due to the degree of disease activity. An increased proportion of caesarean section deliveries in women with coeliac disease was present in the older age groups, again likely due to older maternal age rather than a disease effect. These results indicate that the risks of adverse pregnancy related outcomes for women with coeliac disease are not markedly raised.

These findings are in contrast with those recently reported by Ludvigsson et al who examined adverse fetal outcome in a large population based cohort study. They found that women who had undiagnosed coeliac disease at the time of delivery were more likely to have a preterm birth, caesarean section, or have an offspring with intrauterine growth retardation, low birth weight, or very low birth weight. In contrast, maternal coeliac disease diagnosed before birth was not associated with adverse fetal outcomes. While they adjusted their analyses for various factors, the proportion of mothers with undiagnosed disease in the later period (1996–2001) was small, so their findings may not be generalisable to contemporary undiagnosed coeliac disease. For example, people with a more serious illness may have remained undiagnosed for longer prior to the development (and availability) of endoscopic biopsies and serological markers.

CLINICAL IMPLICATIONS OF BASIC SCIENCE ADVANCES

Steps in coeliac disease pathogenesis

Our understanding of the key steps underlying the intestinal inflammatory response to coeliac disease has increased dramatically in recent years. These steps include: (i) a
(putative) direct response of the epithelium via the innate immune system to toxic proteins in wheat gluten, (ii) modification of wheat gluten proteins by tissue transglutaminase, (iii) role of HLA-DQ2 in presenting toxic wheat proteins to T cells, and (iv) identification of key toxic protein sequences in wheat (fig 3). These advances have introduced the possibility of novel therapeutics (distinct from the gluten free diet) to treat coeliac disease.

The work of Dicke and Frazer in the 1950s identified the protein component of wheat (gluten) as the toxic fraction. Toxic sequences are now identified in both gliadin and glutenin components as well as similar proteins in rye and barley. Cereals are polyploid in nature which combined with the large allelic variation present in all gluten genes makes even gluten from a single wheat variety a complex mixture. However, the general structure of the protein families and the relevance of the high proline (P) and glutamine (Q) content to human coeliac disease is now understood. Interestingly, the fact that many gliadin peptides possess bulky hydrophobic amino acids followed by proline blocks the activity of intestinal peptidases such as pepsin and chymotrypsin.68 69 Thus gluten peptides able to stimulate T cells (such as a recently described 33mer sequence) are resistant to degradation by all gastric, pancreatic, and intestinal brush border membrane proteases in the human intestine.70

Several recent reports have suggested that one of the first events in coeliac disease pathogenesis may be a direct effect of certain wheat peptides, distinct from those recognised by T cells, on the intestinal epithelium. One such peptide, wheat A-gliadin p31-43 (LGQQQPFPPQPY) or p31-49 induces changes associated with coeliac disease on intraduodenal administration,71 and in vitro in biopsy based studies.72 73 Changes were observed in patients within four hours, which is surprisingly rapid for a purely T cell mediated response.

More recent work demonstrated that this peptide appears to induce interleukin 15, a key cytokine involved in T cell activation, and preincubation with the peptide permits later activation of biopsies by known T cell stimulatory wheat gluten sequences.74 Interleukin 15 also appears to induce expression of a stress molecule, MICA, on enterocytes and upregulates NKG2D receptors on intraepithelial lymphocytes. The interaction between enterocyte MICA and lymphocyte NKG2D results in direct enterocyte killing, and is likely to be one way villous atrophy occurs.75 76 Direct effects of gliadin on enterocytes may also increase intestinal permeability through release of zonulin and effects on intracellular tight junctions.77 Surface tissue transglutaminase may have a role in innate immune signalling by p31-43 in coeliac disease.78 More precise details of these mechanisms remain to be elucidated. It is not known whether enterocytes, macrophages/dendritic cells, or another cell type in the small intestinal mucosa are directly activated by p31-43/49, what receptor mechanism is involved, and why these events should be coeliac disease specific.

Involvement of the human leucocyte antigen region (HLA) in coeliac disease was first suggested by serotype based association studies. More detailed analyses at the genetic level implicated HLA-DQ2.79 Nearly all patients with coeliac disease possess either the HLA-DQ2 heterodimer (encoded by DQA1*05 and DQB1*02) or HLA-DQ8 (DQA1*03 and DQB1*0302) compared with approximately one third of Caucasian populations. A European study of 1008 coeliac patients found that 90% possessed genetic variants encoding the HLA-DQ2 heterodimer (in various forms), 4% with partial HLA-DQ2 (DQB1*02 without DQA1*05), 2% with partial HLA-DQ2 (DQA1*05 without DQB1*02), and 6% HLA-DQ8 without DQ-2.80 Our current understanding of coeliac disease susceptibility implies possession of HLA-DQ2 is necessary but
not sufficient for coeliac disease development (as it is also possessed by 30% of the healthy Caucasian population). Nevertheless, genetic testing for HLA-DQ is a useful cost effective test to exclude coeliac disease in individuals already following a gluten free diet. Interestingly, HLA-DQ2 can be encoded in several different ways, leading to variation in the proportion of HLA-DQ2 molecules present. Individuals homozygous for HLA-DQB1*02 appear to be at highest risk of coeliac disease. The functional role of HLA-DQ2 in coeliac disease is now clearly defined and explains the genetic association. Cells able to present toxic gluten peptides to T cells do so via HLA-DQ2. Recent work has even identified the crystal structure and kinetics of dominant wheat gluten peptide binding to HLA-DQ2 (fig 4).80 81

The function of the HLA class II molecule—to present short peptides to T cells—implied that specific dietary wheat, rye, and barley peptides might be presented via HLA-DQ2 in coeliac disease. Although intestinal T cells specific for wheat gluten were first identified in 1993,82 it was only with the discovery that intestinal T cells specifically recognise deamidated gluten peptides that more precise identification was possible.83 HLA-DQ2 preferentially binds peptides with negatively charged amino acids present in key positions. Tissue transglutaminase (the target of the antientomysial autoantibody response in coeliac disease) plays a key role in conversion of specific gluten amide residues to glutamate in the intestinal mucosa, generating negatively charged amino acids better able to bind HLA-DQ2.84 In the intestine, tissue transglutaminase is found just below the epithelium and in the brush border. Deamidation of glutamine residues within a protein sequence is biochemically predictable.84 It remains unclear however why antitissue transglutaminase antibodies are such specific and sensitive indicators of coeliac disease. Such antibodies may recognise transglutaminase-wheat peptide crosslinked complexes85 although whether these have a primary role in disease pathogenesis or are a bystander secondary phenomenon is uncertain.

Identification of the key dietary wheat, rye, and barley peptides presented by T cells is critical for immunologically based therapies aimed at inducing tolerance and attempts at genetic modification of grains to render them non-toxic. Initial presentation of dietary antigen to naive T cells occurs in the mesenteric lymph nodes; these cells recirculate in peripheral blood via the thoracic duct, and home back to the intestine via specific cell adhesion molecules (fig 3). The majority of studies have focused on intestinal T cell lines and clones generated in vitro from small bowel biopsy samples. These methods have identified a large number of different HLA-DQ2 restricted peptides from wheat α/β, γ, and ω gliadins and low molecular weight glutenins,84 86–88 sequences from rye and barley homologous to wheat peptides,89 and a sequence from oat avenins.90 91 However, whether such intestinal biopsy derived T cells generated artificially over many weeks are truly representative of responses in vivo has been unclear. Furthermore, consistency of responses across coeliac individuals has been variable. Arentz-Hansen et al found intestinal T cells responsive to one of two overlapping peptides (QLQPFPQPELPY, PQPELPYPQPELPY) in all 17 HLA-DQ2 coeliac subjects. In contrast, another study found poor consistency among 20 coeliac subjects.92 Methodological differences are likely to explain these variations but raise concerns as to the relevance of identified peptides to human disease in vivo.

An alternative strategy has been developed by Anderson et al, and uses peripheral blood from coeliac subjects drawn after oral gluten challenge.93 In individuals following a gluten free diet for a minimum of two weeks, peripheral blood T cell responses can be reliably detected within a window of three days to two weeks after in vivo oral bread challenge.94 That these T cells are HLA-DQ2 restricted and express gut homing molecules strongly suggests the assay is detecting freshly activated cells recirculating via the thoracic duct (fig 3) and might provide a more accurate picture of the in vivo response.

**Key recent advances and unanswered questions in mechanisms of coeliac disease pathogenesis**

**Advances**

- HLA-DQ2 presents T cell stimulatory wheat gluten peptides.
- Tissue transglutaminase modifies gluten peptides to generate more potent T cell stimulatory sequences.
- Immunodominant T cell stimulatory gluten peptides defined.
- Gluten peptides may also activate the innate immune system.
- Resistance of toxic gluten peptides to degradation in the intestine.

**Questions**

- Mechanisms underlying innate immune system activation by gliadin peptides.
- Does the autoantibody response to tissue transglutaminase have a pathogenic role?
- How gluten peptides enter the intestinal mucosa, and mechanisms of presentation to T cells.
- Identification of further genetic (and environmental) factors predisposing to coeliac disease.
- Factors regulating oral tolerance and suppression of immune responses to gluten.
- Can a good animal model of coeliac disease be generated, particularly to study novel therapeutics?

---

**Figure 4** Crystal structure of immunodominant wheat gluten peptide binding to HLA-DQ2. Putative hydrogen bonding network (red dashes) between DQ2 (α, β chains in green, blue) and α1-gliadin epitope (amino acids PFQPQPELPY, underlining shows tissue transglutaminase modified residue) are shown. DQ2 side chains engaged in hydrogen bonding are shown in grey. Atoms depicted in yellow (carbon), blue (nitrogen), and red (oxygen). Reprinted from Kim et al with permission (copyright 2004 National Academy of Sciences, USA).
**Oats and the gluten free diet**

Historically there was concern that oats may not be safe in coeliac disease. However, the trial by Janatuinen *et al* showing no adverse effects after 6–12 months of dietary oats in patients with coeliac disease was reassuring and has been confirmed by numerous recent studies. Indeed, little effect has been observed on small intestinal mucosal biopsies and in general oats have been well tolerated.

This appears true for both adults and children. Janatuinen *et al* have also reported five year follow up data confirming their initial findings of no obvious harm. While there have been concerns about the quality of oats in some countries (with respect to gluten contamination) it seems that in order to diversify the gluten free diet and hence encourage compliance, oat containing foods should be encouraged for most patients. However, a handful of patients have been reported who do appear to show both clinical and immunological responses to a pure oat product.

**Novel therapeutic possibilities**

The finding that one of the key T cell stimulatory peptides in coeliac disease is resistant to breakdown by intestinal proteases has created interest in digesting these peptides by dietary supplements to remove toxicity. Bacterial prolylendopeptidases can degrade the 33mer T cell stimulatory peptide described by Shan *et al*, and have been commercially produced. Very high concentrations of prolyl-endopeptidase have been shown in biopsy studies to reduce the amount of immunostimulatory gliadin peptides (both innate immune and T cell activating) reaching the mucosa. Whether these therapies will work as dietary supplements awaits human in vivo trials. Such supplements may be able to prevent inadvertent low level gluten exposure even if a full gluten containing diet cannot be achieved.

Attempts to induce immune tolerance are now being attempted in several diseases. For example, treatment with anti-CD3 antibodies (targeted against the T cell receptor) in type 1 diabetes induces transferable T cell mediated tolerance involving the CD4+CD25+ regulatory subset mediated by transforming growth factor β. More targeted therapies aimed at inducing antigen specific tolerance are being developed for type 1 diabetes and such strategies should be possible in coeliac disease. Identification of dominant wheat protein epitopes in coeliac disease has been a key step towards such therapies.

Alternatively, it may be possible to generate wheat (and other cereals) with absent or reduced immunogenicity by selective breeding or genetic modification. Certain varieties of ancient wheats appear to have fewer toxic T cell sequences. Whether it will be possible to breed commercially useful crops, with the necessary properties (for example, baking qualities) and overcome all T cell stimulatory sequences (including in glutenins, and for DQ8 coeliac disease) remains highly uncertain.

Finally, other strategies are also suggested by advances in our understanding of coeliac disease pathogenesis. Blocking tissue transglutaminase mediated deamidation of gluten peptides, zonulin mediated increases in intestinal permeability, HLA-DQ2 peptide interactions, or MICA-NKG2D interactions are all possible therapeutic targets although they may be limited by toxicity. Methods have also been developed to sensitively screen for T cell stimulatory peptides in foods to better guarantee food safety for coeliac disease patients.

---

**DIAGNOSTICS AND THERAPEUTICS**

**Which serological test?**

In the 1980s, Chorzelski *et al* described the production of antiendomysial antibodies in people with dermatitis herpetiformis and coeliac disease. Endomysium is a connective tissue protein found in the collagenous matrix of human and monkey oesophagus. Antibodies to endomysium can be measured in serum with the use of indirect immunofluorescence. The autoantigen recognised by endomysial antibody is tissue transglutaminase, whose role in the pathogenesis of coeliac disease is described above. The IgA antiendomysial antibody test can use either monkey oesophagus or human umbilical cord as substrate and its diagnostic utility has been shown to be very good, with specificity estimated at 99% and sensitivity over 90%. However, the test is labour intensive and qualitative so requires money, time, and expertise to perform. This has led to the development of enzyme linked immunosorbent assay based tests for measurement of IgA tissue transglutaminase antibody levels that are of comparable sensitivity and specificity to the antiendomysial antibody test. Measuring tissue transglutaminase antibody levels is quicker, easier, and quantitative, so has clear advantages over the antiendomysial antibody test. Both tests have superseded the use of antigliadin antibodies, which although of some use have subsequently been shown to have inferior diagnostic accuracy with sensitivity as low as 76%. Further improvements in diagnostic accuracy of the antisera tissue transglutaminase antibody test have been made by use of recombinant human rather than guinea pig transglutaminase in the assay kits. Standardisation and quality control of diagnostic tests for coeliac disease is an important issue.

Coeliac disease has an association with IgA deficiency so it is possible to incorrectly label a person as not having coeliac disease in such cases, particularly when using the IgA dependent immunofluorescence endomysial antibody test. Recently, improvements in techniques for measuring tissue transglutaminase have allowed simultaneous measurement of low serum IgA in the same assay. Although serology appears very sensitive at detecting people with coeliac disease, it is intriguing that some cases of apparent seronegative coeliac disease occur, even in the presence of normal serum IgA. One explanation is that antibody expression is lower in milder mucosal lesions although other possibilities have been proposed.
CONCLUSIONS
Coeliac disease is evidently much more common in Caucasian populations than previously thought. Several large population-based studies estimate the prevalence at ~1%. Further well conducted population-based studies suggest that the overall risks of various morbidities and mortality in treated coeliac disease (as diagnosed in current UK practice) are relatively minor. From an individual perspective, both the clinicians that manage their care and coeliac disease patients now have reasonably precise information to inform them of the actual risks to their health in terms of a range of morbidities and life expectancy. Published guidelines on the management of coeliac disease are now available although some need updating in the light of these recent studies.25 26 28 121 124 Clearly some individuals may be at higher risk of adverse events than others, and identifying those people who might benefit from further intervention in addition to a gluten free diet is a clinical challenge needing further research. Equally, others are at low risk of adverse events, questioning the need for ongoing hospital follow up.

Advances in understanding coeliac disease pathogenesis at a basic science level have opened up prospects for novel diagnostics and therapeutics, and made coeliac disease one of the best understood autoimmune disorders.

ACKNOWLEDGEMENTS
We thank Prof Richard Logan, Dr Geoff Holmes, and Dr Robert Anderson for comments on the manuscript. DAVH is funded by a Wellcome Trust Clinician Scientist Fellowship and Coeliac UK.

Conflict of interest: declared (the declaration can be viewed on the Gut-website at http://www.gutjournal.com/supplemental).

Authors’ affiliations
D A van Heel, Institute of Cell and Molecular Science, Barts and The London, Queen Mary’s School of Medicine and Dentistry, London, UK
J West, Division of Epidemiology and Public Health, University of Nottingham Medical School, Nottingham, UK

REFERENCES
J Exp Med modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease patients. 

Biochemistry outcome of pregnancy.

Gut puerperium.


Hum Immunol TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells.


J Exp Med Tissue transglutaminase selectively recognizes epitopes that cluster in regions of gliadins rich in proline residues.

Hum Immunol Specificity of tissue transglutaminase selectively recognized by IgA antibodies to human tissue transglutaminase antibody ELISA kits.


J Pathol Celiac lesion T cells recognize epitopes that cluster in regions of gliadins rich in proline residues. 


Lancet 2005; 328:218–23

Lancet 1999; 352:218–23


Recent advances in coeliac disease

D A van Heel and J West

*Gut* 2006 55: 1037-1046
doi: 10.1136/gut.2005.075119

Updated information and services can be found at:
[http://gut.bmj.com/content/55/7/1037](http://gut.bmj.com/content/55/7/1037)

These include:

**Supplementary Material**
Supplementary material can be found at:
[http://gut.bmj.com/content/suppl/2006/06/08/55.7.1037.DC1](http://gut.bmj.com/content/suppl/2006/06/08/55.7.1037.DC1)

**References**
This article cites 126 articles, 37 of which you can access for free at:
[http://gut.bmj.com/content/55/7/1037#BIBL](http://gut.bmj.com/content/55/7/1037#BIBL)

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections

Coeliac disease (537)

Notes

To request permissions go to:
[http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to:
[http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to:
[http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)